"Super Trastuzumab" Extends PFS in Late-Line Breast Cancer.
Margetuximab outperformed trastuzumab in a phase III, head-to-head trial of the two anti-HER2 agents among patients with HER2-positive metastatic breast cancer. The new antibody drug was engineered for enhanced immune activity against HER2-expressing tumor cells.